Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China

Overview of attention for article published in Frontiers in Pharmacology, August 2022

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 9 Mendeley

So far, Altmetric has seen 1 X post from an account with 5,881 followers.

New Research: Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China https://t.co/3GNDtU2zsQ #pharmacology

25 Aug 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.